When depression persists despite conventional treatment, IV ketamine may offer another treatment pathway for carefully selected adults, particularly those living with treatment-resistant depression. At Ketamine Wellness Florida, care begins with an individualized physician evaluation, medical screening and a realistic discussion of the evidence.
Depression can affect mood, motivation, concentration, sleep, appetite, relationships, work, physical energy and the ability to experience pleasure. For some people, symptoms improve with psychotherapy, antidepressant medication or a combination of treatments.
Others continue to experience significant symptoms despite appropriate treatment attempts. This is commonly described as treatment-resistant depression, although the exact clinical definition can vary.
Ketamine has received substantial scientific interest because its pharmacology differs from conventional antidepressants. Rather than acting primarily through serotonin, norepinephrine or dopamine, ketamine influences glutamate signaling and NMDA receptors.
Clinical trials have demonstrated that antidepressant effects can emerge rapidly in some patients. That does not mean every patient responds, that improvement is permanent, or that ketamine should replace comprehensive psychiatric treatment.
Some of the best-known ketamine studies have enrolled adults with treatment-resistant major depression. Randomized controlled trials have found greater short-term improvement in depressive symptoms after IV ketamine compared with control conditions in selected patient populations.
A major reason ketamine changed the depression research landscape is the speed with which effects have appeared in some studies. Improvements have been observed within hours or within the first day after treatment rather than only after several weeks.
Research includes adults experiencing major depressive episodes, with contemporary systematic reviews continuing to evaluate both antidepressant outcomes and safety.
Ketamine's effects on glutamatergic signaling and NMDA receptors distinguish it pharmacologically from most traditional antidepressants and continue to be studied as part of its antidepressant mechanism.
Rapid improvement after ketamine does not necessarily mean permanent remission. Researchers continue to study repeated treatment, maintenance strategies and the durability of response.
Responsible ketamine therapy begins with realistic expectations rather than promises about a specific result.
Clinical studies report meaningful improvement among some participants, but response varies. A physician cannot reliably predict in advance whether an individual patient will respond or how strongly.
Antidepressant effects may emerge quickly in some patients, but improvement can diminish. Follow-up and longer-term treatment planning remain important.
Psychotherapy, medication management, sleep, medical care, social support and other evidence-based treatments may remain important even when ketamine becomes part of the treatment plan.
Unipolar major depression, bipolar depression, trauma-related symptoms, substance-related conditions and other psychiatric presentations require different diagnostic and treatment considerations.
Blood pressure, cardiovascular health, medications, substance use, pregnancy, psychiatric history and other clinical factors can influence whether IV ketamine is appropriate.
Depression involves complex biological systems rather than one neurotransmitter or one brain pathway. Ketamine research has helped expand attention beyond the traditional monoamine model.
Ketamine is a noncompetitive antagonist at NMDA receptors, which are involved in glutamate signaling. This differs from the primary pharmacologic targets of most commonly prescribed antidepressants.
Glutamate is the brain's major excitatory neurotransmitter. Research into ketamine has focused substantially on how modifying glutamatergic transmission may produce downstream changes related to mood regulation and antidepressant response.
Experimental research suggests that ketamine can influence signaling pathways associated with synaptic function and neuroplasticity. These findings are part of the scientific model used to investigate ketamine's unusually rapid antidepressant effects.
Depression is shaped by biological, psychological, social, developmental and medical factors. A plausible molecular mechanism does not establish that ketamine will work for every person or eliminate the need for broader mental-health care.
Candidacy should be determined clinically. A depression diagnosis alone does not automatically make someone an appropriate candidate for IV ketamine.
Depression symptoms, course of illness, previous episodes and relevant psychiatric diagnoses should be reviewed before deciding whether ketamine deserves consideration.
Antidepressant trials, psychotherapy, augmentation strategies and other previous treatments help establish what has been attempted and how the patient responded.
Blood pressure, cardiovascular status and other medical conditions are considered because ketamine can temporarily affect cardiovascular and neurological function.
Prescription medications, psychiatric medications, sedatives, stimulants, supplements and substance use should be reviewed as part of individualized treatment planning.
History of mania, psychosis, substance-use concerns, suicidality and other psychiatric factors may substantially influence assessment and treatment planning.
Treatment should focus not only on depression scores, but also on functioning, motivation, relationships, work, self-care and the patient's broader quality of life.
A structured process helps determine whether IV ketamine is medically appropriate and whether continued treatment makes sense based on tolerability and clinical response.
Speak with our team about your depression history, previous treatments, current medications and questions about IV ketamine.
Relevant medical and psychiatric history, medication use, potential contraindications and treatment goals are reviewed.
When treatment is appropriate, ketamine is administered intravenously in a clinical environment with physiologic monitoring and medical oversight.
Depression symptoms, functioning, tolerability and overall clinical response are reassessed to guide subsequent treatment decisions.
Depression is rarely best understood as a single neurotransmitter problem. Effective long-term care may involve medication, psychotherapy, medical evaluation, sleep treatment, lifestyle changes, social support and treatment of co-occurring psychiatric or medical conditions.
When IV ketamine is appropriate, it can be considered as one component of this larger treatment strategy rather than a replacement for comprehensive mental-health care.
Dr. Jarrod Wilson is a South Florida physician specializing in anesthesiology. He attended medical school at the University of Miami and completed anesthesiology residency training at Mount Sinai Medical Center of Miami Beach.
Ketamine has a long history in anesthesiology. Dr. Wilson's anesthesiology background includes experience with intravenous medications, patient monitoring, physiology and medication safety.
During treatment, ketamine can temporarily alter perception, coordination, blood pressure, heart rate and level of awareness. Appropriate patient selection, individualized treatment and clinical monitoring are therefore important components of care.
Ketamine Wellness Florida provides physician-guided IV ketamine care in Fort Lauderdale within The Remedy Health & Wellness. We serve adults from Fort Lauderdale, Broward County and surrounding South Florida communities who are exploring additional options for difficult-to-treat depression.
If you are researching ketamine for depression, IV ketamine for treatment-resistant depression, ketamine infusions for depression or ketamine therapy in Fort Lauderdale , the first step is a clinical conversation.
Our team can discuss your treatment history, answer questions about the process and determine whether a physician evaluation for IV ketamine may be appropriate.
IV ketamine for depression remains an evolving area of psychiatric medicine. Randomized trials and systematic reviews provide important context while also highlighting unanswered questions regarding durability, patient selection and longer-term treatment.
These answers are educational and cannot determine whether IV ketamine is appropriate for an individual patient.
Speak with the Ketamine Wellness Florida care team in Fort Lauderdale to discuss your treatment history and questions about physician-guided IV ketamine therapy for depression.
When depression persists despite conventional treatment, IV ketamine may offer another treatment pathway for carefully selected adults, particularly those living with treatment-resistant depression. At Ketamine Wellness Florida, care begins with an individualized physician evaluation, medical screening and a realistic discussion of the evidence.
Depression can affect mood, motivation, concentration, sleep, appetite, relationships, work, physical energy and the ability to experience pleasure. For some people, symptoms improve with psychotherapy, antidepressant medication or a combination of treatments.
Others continue to experience significant symptoms despite appropriate treatment attempts. This is commonly described as treatment-resistant depression, although the exact clinical definition can vary.
Ketamine has received substantial scientific interest because its pharmacology differs from conventional antidepressants. Rather than acting primarily through serotonin, norepinephrine or dopamine, ketamine influences glutamate signaling and NMDA receptors.
Clinical trials have demonstrated that antidepressant effects can emerge rapidly in some patients. That does not mean every patient responds, that improvement is permanent, or that ketamine should replace comprehensive psychiatric treatment.
Ketamine has been evaluated in randomized clinical trials and systematic reviews, particularly for major depression that has remained symptomatic despite previous treatment.
Some of the best-known ketamine studies have enrolled adults with treatment-resistant major depression. Randomized controlled trials have found greater short-term improvement in depressive symptoms after IV ketamine compared with control conditions in selected patient populations.
A major reason ketamine changed the depression research landscape is the speed with which effects have appeared in some studies. Improvements have been observed within hours or within the first day after treatment rather than only after several weeks.
Research includes adults experiencing major depressive episodes, with contemporary systematic reviews continuing to evaluate both antidepressant outcomes and safety.
Ketamine's effects on glutamatergic signaling and NMDA receptors distinguish it pharmacologically from most traditional antidepressants and continue to be studied as part of its antidepressant mechanism.
Rapid improvement after ketamine does not necessarily mean permanent remission. Researchers continue to study repeated treatment, maintenance strategies and the durability of response.
Responsible ketamine therapy begins with realistic expectations rather than promises about a specific result.
Clinical studies report meaningful improvement among some participants, but response varies. A physician cannot reliably predict in advance whether an individual patient will respond.
Antidepressant effects may emerge quickly in some patients, but improvement can diminish. Follow-up and longer-term treatment planning remain important.
Psychotherapy, medication management, sleep, medical care, social support and other evidence-based treatments may remain important even when ketamine becomes part of the treatment plan.
Unipolar depression, bipolar depression, trauma-related symptoms, substance-related conditions and other psychiatric presentations require different diagnostic and treatment considerations.
Blood pressure, cardiovascular health, medications, substance use, pregnancy, psychiatric history and other clinical factors can influence whether IV ketamine is appropriate.
Depression involves complex biological systems rather than one neurotransmitter or one brain pathway. Ketamine research has helped expand attention beyond the traditional monoamine model.
Ketamine is a noncompetitive antagonist at NMDA receptors, which are involved in glutamate signaling. This differs from the primary pharmacologic targets of most commonly prescribed antidepressants.
Glutamate is the brain's major excitatory neurotransmitter. Research into ketamine has focused substantially on how modifying glutamatergic transmission may produce downstream changes related to mood regulation and antidepressant response.
Experimental research suggests ketamine can influence signaling pathways associated with synaptic function and neuroplasticity. These findings are part of the scientific model used to investigate ketamine's rapid antidepressant effects.
Depression is shaped by biological, psychological, social, developmental and medical factors. A plausible molecular mechanism does not establish that ketamine will work for every person.
Candidacy should be determined clinically. A depression diagnosis alone does not automatically make someone an appropriate candidate for IV ketamine.
Depression symptoms, course of illness, previous episodes and relevant psychiatric diagnoses should be reviewed before deciding whether ketamine deserves consideration.
Antidepressant trials, psychotherapy, augmentation strategies and other previous treatments help establish what has been attempted and how the patient responded.
Blood pressure, cardiovascular status and other medical conditions are considered because ketamine can temporarily affect cardiovascular and neurological function.
Prescription medications, psychiatric medications, sedatives, stimulants, supplements and substance use should be reviewed as part of individualized treatment planning.
History of mania, psychosis, substance-use concerns, suicidality and other psychiatric factors may substantially influence assessment and treatment planning.
Treatment should focus not only on depression scores, but also on functioning, motivation, relationships, work, self-care and broader quality of life.
A structured process helps determine whether IV ketamine is medically appropriate and whether continued treatment makes sense based on tolerability and clinical response.
Speak with our team about your depression history, previous treatments, current medications and questions about IV ketamine.
Relevant medical and psychiatric history, medication use, potential contraindications and treatment goals are reviewed.
When treatment is appropriate, ketamine is administered intravenously in a clinical environment with physiologic monitoring and medical oversight.
Depression symptoms, functioning, tolerability and overall clinical response are reassessed to guide subsequent treatment decisions.
Depression is rarely best understood as a single neurotransmitter problem. Effective long-term care may involve medication, psychotherapy, medical evaluation, sleep treatment, lifestyle changes, social support and treatment of co-occurring psychiatric or medical conditions.
When IV ketamine is appropriate, it can be considered as one component of this larger treatment strategy rather than a replacement for comprehensive mental-health care.
Dr. Jarrod Wilson is a South Florida physician specializing in anesthesiology. He attended medical school at the University of Miami and completed anesthesiology residency training at Mount Sinai Medical Center of Miami Beach.
Ketamine has a long history in anesthesiology. Dr. Wilson's anesthesiology background includes experience with intravenous medications, patient monitoring, physiology and medication safety.
During treatment, ketamine can temporarily alter perception, coordination, blood pressure, heart rate and level of awareness. Appropriate patient selection, individualized treatment and clinical monitoring are therefore important components of care.
Ketamine Wellness Florida provides physician-guided IV ketamine care in Fort Lauderdale within The Remedy Health & Wellness. We serve adults from Fort Lauderdale, Broward County and surrounding South Florida communities who are exploring additional options for difficult-to-treat depression.
If you are researching ketamine for depression, IV ketamine for treatment-resistant depression, ketamine infusions for depression or ketamine therapy in Fort Lauderdale , the first step is a clinical conversation.
Our team can discuss your treatment history, answer questions about the process and determine whether a physician evaluation for IV ketamine may be appropriate.
IV ketamine for depression remains an evolving area of psychiatric medicine. Randomized trials and systematic reviews provide important context while also highlighting unanswered questions regarding durability, patient selection and longer-term treatment.
These answers are educational and cannot determine whether IV ketamine is appropriate for an individual patient.
Speak with the Ketamine Wellness Florida care team in Fort Lauderdale to discuss your treatment history and questions about physician-guided IV ketamine therapy for depression.